Seattle Genetics Presents Preclinical Data On Its Antibody-Drug Conjugate Technology And SGN-33 Program At AACR

Seattle Genetics, Inc. (NASDAQ:SGEN) announced data from multiple poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) highlighting preclinical findings with its proprietary antibody-drug conjugate (ADC) technology. Preclinical data were also presented on SGN-33, a humanized antibody that is in clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

More: continued here

Filed under: Cancer on April 18th, 2008